Asthma
Conditions
Keywords
Respiratory Tract Diseases, Bronchial Diseases, Anti-asthmatic agents, Anti-asthmatic drugs, Bronchodilators
Brief summary
The purpose of this study is to determine whether patients with asthma are better able to manage and control their symptoms by using one inhaler daily that both prevents as well as treats the symptoms of an asthma exacerbation.
Interventions
DRUGBudesonide/formoterol
DEVICESymbicort® Turbohaler®
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged over 18 * Confirmed diagnosis of mild to moderate asthma by doctor * Currently receiving inhaled corticoid-steroid medicine for treatment of asthma and requiring a review of current asthma treatment
Exclusion criteria
* Women who are pregnant, breast-feeding, or planning pregnancy * Patients with a history of chronic obstructive pulmonary disease * Patients using any beta blocker therapy * Patients receiving steroid tablets or steroid injections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In a real life setting, to compare Symbicort® Single Inhaler Therapy with a patient's previous therapy (including low dose ICS), by assessment of the changes in the Asthma Control Questionnaire score in uncontrolled asthmatic patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in forced expiratory volume in one second (FEV1) | — |
| Change in peak expiratory flow (PEF) | — |
| Patient Reported Outcomes: AQLQ(S), SATQ, RCP-3 scores | — |
Countries
United Kingdom
Outcome results
None listed